Vunakizumab (IL-17A inhibitor)

DRUG3 trials

Sponsors

Suzhou Suncadia Biopharmaceuticals Co., Ltd., Chinese SLE Treatment And Research Group, Fujian Cancer Hospital

Conditions

AdebrelimabLupus Erythematosus, SystemicModerate to Severe Plaque PsoriasisSmall Cell Lung CancerVunakizumab

Phase 1

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

RecruitingNCT06881290

Chinese SLE Treatment And Research GroupLupus Erythematosus, Systemic

Start: 2025-05-19End: 2027-12-01Target: 20Updated: 2025-07-10

Phase 2

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

Not yet recruitingNCT07069270

Fujian Cancer HospitalAdebrelimab, Small Cell Lung Cancer, Vunakizumab

Start: 2025-09-01End: 2028-01-01Target: 28Updated: 2025-07-16

Phase 4

Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

Not yet recruitingNCT06779097

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Moderate to Severe Plaque Psoriasis

Start: 2025-02-28End: 2028-02-29Target: 1564Updated: 2025-01-16